{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":11,"x_thread":5,"podcast":1,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06215118\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06215118","nct_id":"NCT06215118","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06215118. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Non-randomized elranatamab plus iberdomide","label":"Part 1 Dose Escalation","type":"EXPERIMENTAL"},{"description":"Randomized elranatamab plus iberdomide","label":"Part 2 Dose Randomization","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2028-10-15","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":100,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Elranatamab","type":"DRUG"},{"name":"Iberdomide","type":"DRUG"}],"last_update":"2026-09-15","lead_sponsor":"Pfizer","official_title":"A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-11-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Number of participants with dose limiting toxicity (DLT)","timeFrame":"Cycle 1, about 28 days"},{"measure":"Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment","timeFrame":"Assessed from baseline up to 90 days after last dose of study treatment"}],"references":[],"start_date":{"date":"2024-02-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)","url":"https://clinicaltrials.gov/study/NCT06215118"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06215118"}